New Delhi, Mar 17 (UNI) Drugmaker Glenmark Pharmaceuticals Ltd today said its US arm Glenmark Pharmaceuticals Inc (GPI) has commenced marketing and distribution of five Clobetasol Propionate dermatology products in the US market.
The firm is also planning to launch an additional 11 dermatological products in the next one year.
It has acquired the US marketing rights for a line of Clobetasol Propionate products, including Cream, E Cream, Ointment Gel and Topical Solution through a US-based pharmaceutical development company, a statement said.
Clobetasol Propionate is used to treat diseases like eczema and psoriasis, and it is also dispensed to counter auto-immune diseases.
The total sales for the five products for the year ending December 2007 was above 28 million dollars, the statement added.
Based on these recent launches, GPI now has a portfolio of 28 generic products for the US market.
UNI SG SBA ND1250